Erythropoietic Response of Dialyzed Patients to Testosterone Administration

Section: Treatmentsupporting

confidence: 82%

Anemia of the Regular Hemodialysis Patient and its Treatment

Koch

Shaldon

et al. 1974

“…This response has not been observed in the nephrectomized rat [32] nor in hemodialyzed patients treated with fluoxymesterone for a short time, whether they were anephric or not [101]. Richardson and Weinstein [89] have observed a significant rise in hemoglobin level in patients on long term hemodialysis treated with testosterone. More recently, Shaldon et al [92] have shown that this treatment was effective in anephric as well as uremic patients having their kidneys.…”

Section: Treatmentmentioning

confidence: 92%

Hematologic Disorders in Renal Failure

Naets¹

1975

Anemia is a frequent complication of renal failure. As in anemias of other origin, the resulting tissular hypoxia is partially compensated by an increased production of 2,3-diphosphoglycerate in red cells and a shift to the right of the oxygen hemoglobin dissociation curve. Two mechanisms are implicated in this anemia: increased hemolysis and depressed production of red cells. Decreased production of erythropoietin is probably the cause of reduced erythropoiesis, but the role of uremic intoxication has not been unequivocally excluded. In the course of chronic hemodialysis, iron deficiency anemia and occasionally hypersplenism develop. It is noteworthy that blood requirements in anephric patients are two to three times greater than those of nonanephric hemodialyzed patients. Accordingly, bilateral nephrectomy should be restricted to carefully selected cases. At the present time, androgens seem to be the best treatment of renal anemia. Qualitative anomalies of platelets are the main factor responsible for uremic bleeding and are corrected by hemodialysis.

“…An association between anemia and renal failure has been recognized since the original observation of Bright [12], In a few of the early works reporting improvement of anemia during androgen treatment, the drug administered was intramuscular testosterone [13,14], Oral oxymetholone and other Cl 7-alkylated testosterones were selected by other workers, since these drugs have been used with out standing success in hypoplastic anemia, with comparatively between HCC and treatment with oxymethoione and other C17-alky!ated testosterones [2][3][4][5][6][7][8][9][10][11]. The majority of these described patients have had aplastic anemia as the under lying disease [7], others were treated for impotence [6,8], cryptorchidism, hypopituitarism, and paroxysmal noctur nal hemoglobinuria [2], It is important to note that neither our reported case, nor all the other cases have had cirrhosis of liver or hemo chromatosis.…”

Section: Discussionmentioning

confidence: 99%

Androgen-Associated Hepatoma in a Hemodialysis Patient

Zevin¹,

Turani²,

Cohen³

et al. 1981

A patient on hemodialysis treatment developed hepatocellular carcinoma (HCC) after long-term therapy with androgenic anabolic steroids. The tumor progressed very rapidly, and there was no evidence of regression despite discontinuation of the drug. In view of the evidence of an increased incidence of malignancy in patients with chronic uremia and hemodialysis, and of the higher frequency of HCC correlated to treatment with C17-alkylated anabolic steroids, it is necessary to further evaluate the efficiency of this treatment in the aforementioned group of patients.